New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study.
Jie ZhouYixin XuHaitao WangZhilin LiuPublished in: Open medicine (Warsaw, Poland) (2024)
This study has confirmed a causal relationship between HMGCR and PSC risk, suggesting statins targeting HMGCR could enhance PSC patient outcomes.